We often are asked the size of the market for various segments of the bio/pharma contract services industry. In response, we’ve developed a resource page that addresses… Learn more.
Follow the Money to Pharmaceutical Opportunities
Spotlight on BioCryst Pharmaceuticals, Inc.
BioCryst plans to raise $45 million in a secondary public offering.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds for future clinical development of BCX7353, for continued development of its second-generation compounds for HAE and… read on.
CMOs and CROs Have Different Trajectories
A growing number of observers, including the Wall Street analysts that follow the publicly-traded CROs and CMOs, have made statements recently suggesting that the CMO industry is following the trajectory that… See Jim Miller’s Outsourcing Outlook Archive.
The contract dose manufacturing universe includes 280 companies headquartered primarily in North America, Europe, Japan and India. Nearly 61% of those companies pursue contract manufacturing as their primary business, while the others contract manufacture in facilities where they produce their own products. Learn more about the implications for the dose CMO industry.